Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Nov;15(11):664-666.
doi: 10.1038/s41581-019-0200-1.

MENTOR heralds a new era of therapy for membranous nephropathy

Aikaterini Nikolopoulou  1 , Megan Griffith  2
Affiliations
Comment

MENTOR heralds a new era of therapy for membranous nephropathy

Aikaterini Nikolopoulou et al. Nat Rev Nephrol. 2019 Nov.
No abstract available

PubMed Disclaimer

Comment on

  • Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
    Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators. Fervenza FC, et al. N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427. N Engl J Med. 2019. PMID: 31269364 Clinical Trial.

References

    1. Fervenza, F. C. et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 381, 36–46 (2019). - DOI
    1. Cattran, D. C. et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 59, 1484–1490 (2001). - DOI
    1. Howman, A. et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381, 744–751 (2013). - DOI
    1. van den Brand, J. et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 28, 2729–2737 (2017). - DOI
    1. Praga, M. et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 71, 924–930 (2007). - DOI

MeSH terms

LinkOut - more resources